MedTrace Logo

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

NCT04396457 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-03-23

No results posted yet for this study

Summary

To evaluate the efficacy and safety of Pembrolizumab + Pemetrexed in elderly patients with non-squamous non-small cell lung cancer with Programmed cell death (PD) -ligand1 (L1) tumor proportion score (TPS) of less than 50%.

Conditions

  • Non-squamous Non-small-cell Lung Cancer
  • Cancer, Lung

Interventions

DRUG

Pembrolizumab

Human PD-1 Monoclonal antibody

DRUG

Pemetrexed

Antineoplastic antimetabolite

Sponsors & Collaborators

  • Central Japan Lung Study Group

    collaborator UNKNOWN

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • National Hospital Organization Nagoya Medical Center

    lead OTHER

Principal Investigators

  • Yoshihito Kogure, MD, PhD · National Hospital Organization Nagoya Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-25
Primary Completion
2023-05-31
Completion
2024-11-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04396457 on ClinicalTrials.gov